Marcus Vale
Performance Writer
Men 35–50 optimizing energy, body composition and testosterone
Marcus Vale covers performance and metabolic health for men in the thick of midlife — testosterone, training, stress and turning the dad-bod years into the strongest decade yet. Practical, skeptical of fads, and allergic to bro-science.
Latest articles
Why GLP-1 Drugs Last for Days: The Lipid Trick Behind Semaglutide's Half-Life
Native GLP-1 vanishes from your bloodstream in minutes. A fatty-acid tail turns it into a once-weekly shot — but the same trick that buys time also makes the drug harder to manufacture.
Plant-Forward Eating, Reviewed: What 32 Long-Term Studies Actually Show
A 2025 systematic review maps where plant-based eating moves the metabolic needle — and where the evidence still thins out. Here's what a busy 40-year-old should actually take from it.
AI Rewrites the Peptide Drug Pipeline
Three recent papers show machine learning moving from hype to workflow in peptide therapeutics — compressing discovery cycles and flagging safety risks earlier. Here's what changes for a field bottlenecked by synthesis and red-cell toxicity.
The Next Generation of GLP-1s: PYY Analogs, AI-Designed Molecules, and Weekly Insulin
Semaglutide and tirzepatide rewrote the metabolic playbook. The pipeline behind them is already bifurcating — and what arrives next will look less like one blockbuster shot and more like a stack.
Beyond Diabetes: The Expanding—and Uneasy—Frontier of GLP-1 Medicine
A new wave of peer-reviewed evidence shows GLP-1 drugs reaching further into metabolic medicine—while exposing risks that busy men should know before they fill the prescription.
Beyond Weight Loss: How GLP-1s Are Quietly Rewriting Liver, Brain, and Addiction Medicine
A new wave of 2025 research suggests semaglutide and its siblings do far more than shrink waistlines. The evidence is moderate, the implications are not.
GLP-1s Beyond Weight Loss: What the New Heart, Muscle, and Oral-Delivery Data Actually Show
GLP-1 receptor agonists are sprawling past diabetes and obesity into cardiovascular protection, body-composition debates, and pill-form delivery. Here is what the latest wave of evidence supports — and what it doesn't.
Tirzepatide Without Diabetes: What the Meta-Analysis Behind the Hype Actually Shows
A new pooled analysis of randomized trials isolates the non-diabetic obesity population — the use case driving most consumer demand — and quantifies what the dual GIP/GLP-1 agonist actually does, and what it costs.